Milliseconds of variability, now detected by fitness watches, can improve well-being Earlier this year I got an Oura ring to ...

When you're flying on a commercial jet and going through a cloud, it's easy to wonder how pilots know where they're going, ...

Japan’s newly elected Prime Minister Sanae Takaichi has triggered a sharp political storm across East Asia through her recent, highly provocative comments suggesting that a conflict in the Taiwan ...

SINGAPORE– Thailand artist, Ms Jamilah Haji’s artwork, “Dua (Pray for a Blessing)”, which depicts hope and harmony, has ...

Karina Volkova trains in a clinic using a temporary permit that expires in 2027, giving her a narrow window to clear all ...

FMG's John Keeton examines how to tender for a preferred supplier in supporting fleet contracts, achieving value for money, ...

Man' video games and 1,200 other credits between them — offer advice for aspiring actors as they launch a new online course ...

A research team from Virginia Tech has developed initial approaches to remove frost without using energy-intensive heat or ...

Telitacicept is a dual inhibitor of both B-lymphocyte stimulator and a proliferation-inducing ligand, cytokines that promote B cell survival and production of pathogenic galactose-deficient IgA1.

Shares of Vor Bio declined after the company shared plans for a public offering of $100 million of its common stock. The stock fell 26% to $13.90 in after-hours trading on Monday. Shares are down 15% ...

Investing.com -- Vor Biopharma Inc (NASDAQ:VOR) stock plunged 14.9% in after-hours trading Monday after the clinical-stage biotechnology company announced plans for a $100 million public offering of ...